Neuroendocrine Tumour Imaging and Molecular Radiotherapy

Neuroendocrine tumours are a diverse group of relatively rare cancers, with a reported incidence of 9 cases per 100,000 people in 2015.

Recently there have been major advances in their diagnosis, staging and treatment.  The possibility of multiple options to investigate and treat a diverse range of rare tumours represents a challenge for all members of the MDT, not least the radiologist.

The course aims to demystify this disease group and help radiologists achieve optimal management of their patients at the MDT.

It is expected that candidates have prior knowledge of FDG PET-CT imaging before undertaking the tutorials.

Learning Objectives

• Discuss the concept of somatostatin receptor imaging, normal distribution and variants of uptake, as well as some interpretation pitfalls.
• Review and illustrate the clinical indications for performing 68 Ga DOTA-SSA PET-CT, including the staging of well-differentiated NETs, the detection of occult NET primary tumours, and the use of 68 Ga DOTA-SSA PET-CT in evaluating recurrence.
• Discuss the role of 18FDG PET-CT in high- and low-grade neuroendocrine tumours and the potential role of 18F-FDOPA PET-CT.
• Explain the concept of molecular radiotherapy, review patient selection criteria and discuss the evidence for the use of PRRT in NET.